Artikel ; Online: Atomoxetine in the treatment of adults with subthreshold and/or late onset attention-deficit hyperactivity disorder-not otherwise specified (ADHD-NOS): a prospective open-label 6-week study.
CNS neuroscience & therapeutics
2010 Band 16, Heft 1, Seite(n) 6–12
Abstract: The objective of this study was to evaluate the efficacy and tolerability of atomoxetine hydrochloride (ATX) in the treatment of adults with atypical manifestations of attention-deficit hyperactivity disorder (ADHD) (not otherwise specified [NOS]). We ... ...
| Abstract | The objective of this study was to evaluate the efficacy and tolerability of atomoxetine hydrochloride (ATX) in the treatment of adults with atypical manifestations of attention-deficit hyperactivity disorder (ADHD) (not otherwise specified [NOS]). We hypothesized that treatment with ATX will be safe and efficacious for the treatment of adults with ADHD-NOS. This was a 6-week, open-label, prospective treatment study of ATX monotherapy in 45 adult patients with ADHD-NOS assessed using standardized instruments for diagnosis and a robust oral daily dose of up to 1.2 mg/kg/day or 120 mg/day. Symptom severity was assessed with the adult ADHD Investigator Symptom Report Scale (AISRS) and Clinical Global Impression Scale. Treatment with ATX at an average daily dose of 78.7 +/- 27.8 mg was associated with a statistically and clinically significant reduction in ADHD symptoms relative to baseline as assessed through the (AISRS) (-12.1 +/- 8.4; P < 0.001). Using a categorical definition of response (CGI-I much or very much improved), a majority (N = 29; 64%) of subjects were rated as improved at study endpoint. Treatment with ATX was relatively well tolerated. These open-label results suggest that ATX may be safe and effective in the treatment of adults meeting criteria for ADHD-NOS and support the need for further controlled clinical trials of ATX in this population. |
|---|---|
| Mesh-Begriff(e) | Adrenergic Uptake Inhibitors/therapeutic use ; Adult ; Atomoxetine Hydrochloride ; Attention Deficit Disorder with Hyperactivity/drug therapy ; Attention Deficit Disorder with Hyperactivity/physiopathology ; Dose-Response Relationship, Drug ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Pilot Projects ; Propylamines/therapeutic use ; Prospective Studies ; Severity of Illness Index ; Treatment Outcome ; Young Adult |
| Chemische Substanzen | Adrenergic Uptake Inhibitors ; Propylamines ; Atomoxetine Hydrochloride (57WVB6I2W0) |
| Sprache | Englisch |
| Erscheinungsdatum | 2010-01-08 |
| Erscheinungsland | England |
| Dokumenttyp | Clinical Trial ; Journal Article |
| ZDB-ID | 2423461-8 |
| ISSN | 1755-5949 ; 1755-5930 |
| ISSN (online) | 1755-5949 |
| ISSN | 1755-5930 |
| DOI | 10.1111/j.1755-5949.2009.00124.x |
| Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
| Zs.A 4537: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.